Literature DB >> 25877751

JARID1B modulates lung cancer cell proliferation and invasion by regulating p53 expression.

Xudong Shen1, Zhixiang Zhuang1, Yusong Zhang1, Zhigang Chen1, Liqin Shen1, Wangyang Pu1, Lei Chen1, Zhonghua Xu2.   

Abstract

Although three therapeutic modalities (surgical resection, chemotherapy, and radiotherapy) have been established, long-term survival for lung cancer patients is still generally poor. Until now, the mechanisms of lung cancer genesis remain elusive. The JARID1B is a histone demethylase that has been proposed as oncogene in several types of human cancer, but its clinical significance and functional role in human non-small cell lung cancer (NSCLC) remain unclear. In present study, we found that JARID1B was overexpressed in lung cancer cell lines and lung cancer tissues but not in normal lung tissues. The proliferation and invasive potential of lung cancer cells was significantly increased by ectopic expression of JARID1B. Contrarily, RNA interference targeting JARID1B in lung cancer cells significantly decreased the proliferation and invasive potential of cells. Moreover, we also found that the expression of p53 was modulated by JARID1B. Overexpressed JARID1B cell exhibited greatly decreased p53 expression, whereas silencing of JARID1B expression dramatically increased p53 expression at both the messenger RNA (mRNA) and protein levels. Inhibition of p53 by small interfering RNA (siRNA) reversed the shJARID1B-induced suppression of proliferation and invasion. Our results collectively suggested that JARID1B expressed in lung cancer played a role in lung cancer cells proliferation and invasion, which may be partly associated with the p53 expression.

Entities:  

Keywords:  Invasion; JARID1B; Lung cancer; Proliferation; p53

Mesh:

Substances:

Year:  2015        PMID: 25877751     DOI: 10.1007/s13277-015-3418-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  27 in total

1.  The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6.

Authors:  Gouji Toyokawa; Hyun-Soo Cho; Yukiko Iwai; Masanori Yoshimatsu; Masashi Takawa; Shinya Hayami; Kazuhiro Maejima; Noriaki Shimizu; Hirotoshi Tanaka; Tatsuhiko Tsunoda; Helen I Field; John D Kelly; David E Neal; Bruce A J Ponder; Yoshihiko Maehara; Yusuke Nakamura; Ryuji Hamamoto
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-19

2.  The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth.

Authors:  Jun Yang; Adrian M Jubb; Luke Pike; Francesca M Buffa; Helen Turley; Dilair Baban; Russell Leek; Kevin C Gatter; Jiannis Ragoussis; Adrian L Harris
Journal:  Cancer Res       Date:  2010-08-03       Impact factor: 12.701

Review 3.  The oncogenic potential of Jumonji D2 (JMJD2/KDM4) histone demethylase overexpression.

Authors:  Leah C Young; Michael J Hendzel
Journal:  Biochem Cell Biol       Date:  2012-12-05       Impact factor: 3.626

4.  Transient JMJD2B-mediated reduction of H3K9me3 levels improves reprogramming of embryonic stem cells into cloned embryos.

Authors:  Jisha Antony; Fleur Oback; Larry W Chamley; Björn Oback; Götz Laible
Journal:  Mol Cell Biol       Date:  2012-12-21       Impact factor: 4.272

5.  BRIT1 regulates p53 stability and functions as a tumor suppressor in breast cancer.

Authors:  Bo Zhang; Edward Wang; Hui Dai; Ruozhen Hu; Yulong Liang; Kaiyi Li; Guobin Wang; Guang Peng; Shiaw-Yih Lin
Journal:  Carcinogenesis       Date:  2013-06-01       Impact factor: 4.944

Review 6.  P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.

Authors:  Iuliana Shapira; Annette Lee; Reena Vora; Daniel R Budman
Journal:  Crit Rev Oncol Hematol       Date:  2013-06-05       Impact factor: 6.312

Review 7.  Molecular biology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Serge Patrick Nana-Sinkam; Charles A Powell
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

8.  The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover.

Authors:  Kelly Coffey; Lynsey Rogerson; Claudia Ryan-Munden; Dhuha Alkharaif; Jacqueline Stockley; Rakesh Heer; Kanagasabai Sahadevan; Daniel O'Neill; Dominic Jones; Steven Darby; Peter Staller; Alejandra Mantilla; Luke Gaughan; Craig N Robson
Journal:  Nucleic Acids Res       Date:  2013-02-21       Impact factor: 16.971

9.  Jumonji domain-containing protein 2B silencing induces DNA damage response via STAT3 pathway in colorectal cancer.

Authors:  L Chen; L Fu; X Kong; J Xu; Z Wang; X Ma; Y Akiyama; Y Chen; J Fang
Journal:  Br J Cancer       Date:  2014-01-28       Impact factor: 7.640

Review 10.  Targeted therapies in development for non-small cell lung cancer.

Authors:  Thanyanan Reungwetwattana; Grace Kho Dy
Journal:  J Carcinog       Date:  2013-12-31
View more
  13 in total

1.  Genetic heterogeneity within collective invasion packs drives leader and follower cell phenotypes.

Authors:  Elizabeth L Zoeller; Brian Pedro; Jessica Konen; Bhakti Dwivedi; Manali Rupji; Niveda Sundararaman; Lei Wang; John R Horton; Chaojie Zhong; Benjamin G Barwick; Xiaodong Cheng; Elisabeth D Martinez; Matthew P Torres; Jeanne Kowalski; Adam I Marcus; Paula M Vertino
Journal:  J Cell Sci       Date:  2019-10-09       Impact factor: 5.285

2.  KDM5B overexpression predicts a poor prognosis in patients with squamous cell carcinoma of the head and neck.

Authors:  Donghai Huang; Yuanzheng Qiu; Guo Li; Chao Liu; Li She; Diekuo Zhang; Xiyu Chen; Gangcai Zhu; Xin Zhang; Yongquan Tian; Yong Liu
Journal:  J Cancer       Date:  2018-01-01       Impact factor: 4.207

Review 3.  Hypoxia and Inflammation in Cancer, Focus on HIF and NF-κB.

Authors:  Laura D'Ignazio; Michael Batie; Sonia Rocha
Journal:  Biomedicines       Date:  2017-05-09

Review 4.  Histone demethylase lysine demethylase 5B in development and cancer.

Authors:  Mengjiao Han; Wenxia Xu; Pu Cheng; Hongchuan Jin; Xian Wang
Journal:  Oncotarget       Date:  2017-01-31

5.  Targeting JARID1B's demethylase activity blocks a subset of its functions in oral cancer.

Authors:  Nicole D Facompre; Kayla M Harmeyer; Varun Sahu; Phyllis A Gimotty; Anil K Rustgi; Hiroshi Nakagawa; Devraj Basu
Journal:  Oncotarget       Date:  2017-12-15

Review 6.  p53 and metabolism: from mechanism to therapeutics.

Authors:  Fernando M Simabuco; Mirian G Morale; Isadora C B Pavan; Ana P Morelli; Fernando R Silva; Rodrigo E Tamura
Journal:  Oncotarget       Date:  2018-05-04

7.  Jumonji AT-rich interactive domain 1B promotes the growth of pancreatic tumors via the phosphatase and tensin homolog/protein kinase B signaling pathway.

Authors:  Xudong Shen; Guilian Cheng; Liming Xu; Wei Wu; Zhengrong Chen; Peng Du
Journal:  Oncol Lett       Date:  2018-05-02       Impact factor: 2.967

8.  Recognition of Histone H3 Methylation States by the PHD1 Domain of Histone Demethylase KDM5A.

Authors:  James E Longbotham; Mark J S Kelly; Danica Galonić Fujimori
Journal:  ACS Chem Biol       Date:  2021-02-23       Impact factor: 4.634

9.  Prognostic significance of RBP2-H1 variant of JARID1B in melanoma.

Authors:  Łukasz Kuźbicki; Dariusz Lange; Agata Stanek-Widera; Barbara W Chwirot
Journal:  BMC Cancer       Date:  2017-12-15       Impact factor: 4.430

10.  Hepatitis B virus X protein induces hepatic stem cell-like features in hepatocellular carcinoma by activating KDM5B.

Authors:  Xuyang Wang; Naoki Oishi; Tetsuro Shimakami; Taro Yamashita; Masao Honda; Seishi Murakami; Shuichi Kaneko
Journal:  World J Gastroenterol       Date:  2017-05-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.